Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen U.S. Plan by Year
U.S. Plan — Benefit-Responsive Investment Contracts at Contract Value ($M) ($M)
Amgen U.S. Plan: $761M in FY2025, up 10.6% from a year earlier. That is the highest of the 9 years on record here.
Latest, FY2025
761
Period ended Dec 31, 2025
Change on a year earlier
+10.6%
688 in FY2024
History
9 years
Since FY2017
Sources
8
Documents cited below
Where the FY2025 figure comes from
“|| Investments in fully benefit-responsive investment contracts at contract value | 761,085,480 | 688,059,315”
Source: Form 11-K (Retirement & Savings Plan) (amgn-20260611.htm, filed 2026-06-11) ↗
Reported in Form 11-K Amgen Retirement and Savings Plan (U.S.).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Amgen U.S. Plan ($M), annual FY2017–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/plan-us-brc
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.